Verification Pending — official Grants.gov candidate (posted)
RFA-NS-26-001
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Official Grants.gov opportunity RFA-NS-26-001 from National Institutes of Health. Requires full eligibility, amount, controlling deadline, award-type and duplication QA before publication.
FundingApplicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Deadline2026-11-10 (official deadline clock time and time zone must be checked in NOFO)
Last verifiedAtlas review
Required next actionReview the official full announcement, amendments and submission portal requirements before applying.
Broad Eligibility
Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; State governments; Private institutions of higher education; For profit organizations other than small businesses; Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; City or township governments
Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: RFA-NS-26-001
Official listed status: posted
Closing information: 2026-11-10 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; State governments; Private institutions of higher education; For profit organizations other than small businesses; Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; City or township governments
Federal synopsis
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.
Official Grants.gov opportunity and NOFO
From Funding to Implementation · School Health Solution
Turn school-health funding into a clinically capable care model.
Dr. Miltie N9+ can support clinician-directed remote exams in school settings, helping care teams move beyond video-only encounters when a funded program calls for stronger pediatric access.
Source verificationOfficial government source · www.grants.govAtlas last verified this record during its latest review. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
